Abstract Number: 204 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Background/Purpose: RA patients have an increased risk of malignancy1 and deep-vein thrombosis and pulmonary embolism (DVT/PE)2 and high prevalence of anemia.3 The risks of anemia…Abstract Number: 1588 • 2019 ACR/ARP Annual Meeting
Disease Activity and Dysregulated Iron Metabolism: A Potentially Overlooked Mechanism for Anaemia in Patients with Systemic Lupus Erythematosus?
Background/Purpose: Haematological manifestations of SLE are common with anaemia reported in approximately 50% of cases, yet the role of altered iron metabolism is poorly understood.…Abstract Number: 2875 • 2019 ACR/ARP Annual Meeting
Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
Background/Purpose: Anemia, thrombocytopenia and leukopenia in RA patients treated with non-Janus Kinase 1 (JAK1) selective inhibitors may be due to inhibition of hematopoietic growth factors…Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…Abstract Number: 436 • 2017 ACR/ARHP Annual Meeting
Baseline Anemia As a Predictor of Radiographic Progression in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analyses from Two Phase 3 Trials
Background/Purpose: Anemia in patients with rheumatoid arthritis (RA) can help to identify those with more rapid erosive disease.1,2 Tofacitinib is an oral Janus kinase inhibitor…Abstract Number: 2381 • 2017 ACR/ARHP Annual Meeting
Hematologic Abnormalities during the Use of Low Dose Methotrexate for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Methotrexate (MTX) is known to increase the risk of cytopenias, but the prevalence of hematologic abnormalities among patients taking low dose MTX is poorly…Abstract Number: 1356 • 2016 ACR/ARHP Annual Meeting
Correlation of Erythrocyte Sedimentation Rate with Glycohemoglobin Values and Other Patient Factors
Background/Purpose: The erythrocyte sedimentation rate (ESR) is a laboratory test commonly used in clinical practice as an assessment of systemic inflammation. The glycohemoglobin (A1c) measures…Abstract Number: 1803 • 2016 ACR/ARHP Annual Meeting
General Features of SLE Patients Presenting with Autoimmune Hemolytic Anemia
Background/Purpose: Anemia in systemic lupus erythematosus (SLE) might have various etiologies; however, autoimmune hemolytic anemia (AIHA) is the characteristic hematologic feature. AIHA might be primary…Abstract Number: 831 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Decreases the Frequency of Endoscopic Therapy for Gastric Antral Vascular Ectasia in Patients with Systemic Sclerosis
Background/Purpose: Gastric antral vascular ectasia (GAVE) is an increasingly recognized cause of upper gastrointestinal bleeding in patients with systemic sclerosis (SSc). These patients may require…Abstract Number: 728 • 2015 ACR/ARHP Annual Meeting
Autoimmune Hemolytic Anemia and Thrombocytopenia in a Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey : Clinical Associations and Effect on Disease Damage and Survival
Background/Purpose: Hematologic involvement is common in patients with SLE. Thrombocytopenia and autoimmune hemolytic anemia (AIHA), prevalences of which have been reported as 10-40 % and…Abstract Number: 1912 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency
Background/Purpose: Renal involvement is relatively common in rheumatoid arthritis (RA) patients. Recent randomized controlled trials of anti-tumor necrosis factor-α (anti-TNFα) showed that the concomitant administration…Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting
Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus
Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…Abstract Number: 2374 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects
Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there…Abstract Number: 735 • 2013 ACR/ARHP Annual Meeting
Clinical Research Of Microscopic Polyangiitis Combined With Autoimmune Hemolytic Anemia
Background/Purpose: Autoimmune hemolytic anemia (AIHA) and Microscopic polyangiitis (MPA) are both rare autoimmune conditions. AIHA is caused by autoantibody-induced hemolysis (the premature destruction of circulating…
ACR Meeting Abstracts